Kwang Dong Pharmaceutical Co., Ltd.

A009290

KR7009290008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 18/06/2024 BST			5-day change	1st Jan Change
6,600 ^KRW	-1.20%		-0.45%	-11.17%

05-16	Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-18	Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Oxford Cancer Biomarkers Ltd announced that it has received funding from Kwang Dong Pharmaceutical Co., Ltd.

June 02, 2019

Oxford Cancer Biomarkers Ltd announced that it has received a round of funding from Kwang Dong Pharmaceutical Co., Ltd. (KOSE:A009290) on June 3, 2019

Latest news about Kwang Dong Pharmaceutical Co., Ltd.

Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea	01-29	MT
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	01-01	CI
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	12-28	CI
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion	12-28	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 11, 2023.	30/06/23	CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 11, 2023, has closed with 1,000,000 shares, representing 2.43% for KRW 6,228.66 million.	27/06/23	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares.	11/04/23	CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	10/04/23	CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea	27/03/23	MT
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	17/03/22	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Oxford Cancer Biomarkers Ltd announced that it has received funding from Kwang Dong Pharmaceutical Co., Ltd.	02/06/19	CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 6, 2018.	05/03/19	CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 6, 2018.	05/03/19	CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 6, 2018 has closed with 1,000,000 shares, representing 1.91% for KRW 7,098.83 million.	04/03/19	CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback.	06/12/18	CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	05/12/18	CI

Chart Kwang Dong Pharmaceutical Co., Ltd.

Duration

Period

Chart Kwang Dong Pharmaceutical Co., Ltd.

More charts

Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KWANG DONG PHARMACEUTICAL CO., LTD.	-11.17%	192M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.80%	43.26B
OTSUKA HOLDINGS CO., LTD.	+17.47%	21.6B
SANDOZ GROUP AG	+21.73%	15.93B
CIPLA LIMITED	+23.95%	15.1B
ZYDUS LIFESCIENCES LIMITED	+57.96%	12.95B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-16.22%	6.29B
ASPEN PHARMACARE HOLDINGS LIMITED	+19.77%	6.04B
STADA ARZNEIMITTEL	-8.87%	5.73B